Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome
Key claim: A Phase I study is testing the safety and tolerability of allogeneic umbilical cord mesenchymal stem cells (HeXell-2020) in elderly subjects with mild to moderate frailty syndrome.
Abstract
This is a phase I study to investigate the safety, and Tolerability of HeXell-2020 in Elderly Subjects with Mild to Moderate Frailty Syndrome.
HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.
Why this matters
A Phase I study is testing the safety and tolerability of allogeneic umbilical cord mesenchymal stem cells (HeXell-2020) in elderly subjects with mild to moderate frailty syndrome.